TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23918952

Group type: EXPERIMENTAL
Intervention: Apatinib 850 mg once daily (group B)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Apatinib 425 mg twice daily (group C)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 144
Study: 22127969

Group type: EXPERIMENTAL
Intervention: Daily oral cyclophosphamide (CYC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CYC cumulative dose
Number of subjects: 42
Study: 19388967

Group type: EXPERIMENTAL
Intervention: Smoking and family history of diabetes
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: High physical activity
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Large waist circumference
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: High body mass index (BMI)
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: BMI and waist circumference
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Short height
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Short height and low hip circumference
Number of subjects: 3164
Study: 16783073

Group type: EXPERIMENTAL
Intervention: Vitix (antioxidants, superoxide dismutase, and catalase)
Number of subjects: 25
Study: 15139572

Group type: EXPERIMENTAL
Intervention: High intensity physical group training in water
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High intensity physical group training on land
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study: 9588607

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage ingestion (4 mL x kg(‐1) every 15 min during exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage ingestion (C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo beverage ingestion (P)
Number of subjects: 10
Study: 7974686

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 2642616

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 985152

Group type: EXPERIMENTAL
Intervention: Adjuvant nitrosourea chemotherapy (carmustine, lomustine, or semustine)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 62
Study: 30419232

Group type: EXPERIMENTAL
Intervention: Competitive volleyball exercise (n=16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Noncompetitive volleyball exercise (n=16)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 48
Study: 28032910

Group type: EXPERIMENTAL
Intervention: Everolimus co-administration with octreotide LAR
Number of subjects: 182
Study: 26048580

Group type: EXPERIMENTAL
Intervention: Baclofen (30-270mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 23383686

Group type: EXPERIMENTAL
Intervention: Resistance exercise with super-imposed whole-body vibrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resistance exercise without super-imposed whole-body vibrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (Resistance exercise with and without WBV)
Number of subjects: 0
Study: 22453228

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Behavioral therapy
Number of subjects: 20
Study: 18785848

Group type: EXPERIMENTAL
Intervention: Low-power He-Ne laser (output power 0.2 mW) for 10 min, applied eight times in the first 3-month period after non-surgical mechanical periodontal treatment.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control sites received no additional treatment after non-surgical mechanical periodontal treatment.
Number of subjects: 16
Study: 17475006

Group type: EXPERIMENTAL
Intervention: Intermediate care at a community hospital (n=72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: General hospital care (n=70)
Number of subjects: 142
Study: 15804807

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study: 11266030

Group type: EXPERIMENTAL
Intervention: Screening program for diabetic nephropathy (urine samples collected from all patients)
Number of subjects: 247
Study: 9034838

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.0015% twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 30
Study: 8302442

Group type: EXPERIMENTAL
Intervention: 40 mg of Nicardipine retard twice a day (b.i.d.) for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Captopril in a dose of 25 mg (b.i.d.) for 8 weeks
Number of subjects: 36
Study: 2957900

Group type: EXPERIMENTAL
Intervention: Selective coronary injection of echocontrast medium through the central lumen of the angioplasty catheter before balloon inflation (group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Echocontrast medium injected through the introducer catheter positioned in the left main coronary artery during balloon inflation (group B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intracoronary echocontrast injections (both groups)
Number of subjects: 14
Study: 29298277

Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 41
Study: 26397376

Group type: EXPERIMENTAL
Intervention: Antibiotics for four days
Number of subjects: 336

Group type: COMPARATOR
Intervention: Antibiotics until two days after clinical symptom resolution
Number of subjects: 336
Study: 25133794

Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg once daily for 1 year
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 21956447

Group type: EXPERIMENTAL
Intervention: Psilocybin (260 μg/kg p.o.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Psilocybin (260 μg/kg p.o.) + Ketanserin (40 mg p.o.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ketanserin (40 mg p.o.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20159701

Group type: COMPARATOR
Intervention: Postoperative general anesthesia and intravenous analgesia (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraoperative general anesthesia combined with thoracic epidural anesthesia with postoperative epidural analgesia (group B)
Number of subjects: 60
Study: 19123322

Group type: EXPERIMENTAL
Intervention: Tangyikang (TYK) combined with insulin therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Insulin therapy alone (Control)
Number of subjects: 74
Study: 15850470

Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha-2a 180 microg/week + RBV 1000 or 1200 mg/day + AMA 200 mg/day
Number of subjects: 362

Group type: COMPARATOR
Intervention: IFN alpha-2a 3 MU tiw + RBV 1000 or 1200 mg/day + AMA 200 mg/day
Number of subjects: 362

Group type: COMPARATOR
Intervention: IFN alpha-2a 3 MU tiw + RBV 1000 or 1200 mg/day
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha-2a + RBV + AMA
Number of subjects: 362

Group type: COMPARATOR
Intervention: IFN alpha-2a + RBV + AMA
Number of subjects: 362

Group type: COMPARATOR
Intervention: IFN alpha-2a + RBV
Number of subjects: 362
Study: 12861852

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg total dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 28

Group type: COMPARATOR
Intervention: Acetaminophen (paracetamol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nimesulide
Number of subjects: 28
Study: 10577848

Group type: COMPARATOR
Intervention: One cycle of high-dose cytarabine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Three or more cycles of high-dose cytarabine
Number of subjects: 50
Study: 8733038

Group type: EXPERIMENTAL
Intervention: Lisinopril (10‐20 mg once daily)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Nifedipine (20‐40 mg twice daily)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 335

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 335

Group type: COMPARATOR
Intervention: Lisinopril and Nifedipine
Number of subjects: 335
Study: 1289173

Group type: EXPERIMENTAL
Intervention: Pancreatic extracts (acid‐protected microtablets; Panzytrat ‐20,000; 5 x 2 capsules/day; proteases/capsule 1,000 Pharmacopoea europaea units) for 14 days followed by placebo for another 14 days.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for 14 days followed by pancreatic extracts for another 14 days.
Number of subjects: 47
Study: 6146033

Group type: EXPERIMENTAL
Intervention: 20 g sucrose taken at the end of a mixed meal (meal B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isocaloric amounts of starch (meal A)
Number of subjects: 18
Study: 31426685

Group type: EXPERIMENTAL
Intervention: TIVA+TEA
Number of subjects: 40

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 40
Study: 29323577

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC) - 1.5 mg estradiol and 2.5 mg nomegestrolacetate
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Risk use of alcohol with COC
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 27825415

Group type: EXPERIMENTAL
Intervention: Intranasal DEX 1 μg/kg (Group D1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intranasal DEX 2 μg/kg (Group D2)
Number of subjects: 41
Study: 26093980

Group type: EXPERIMENTAL
Intervention: bOPV short
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: bOPV standard
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: mOPV1 short
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: mOPV1 standard
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: tOPV standard
Number of subjects: 1000
Study: 23589502

Group type: EXPERIMENTAL
Intervention: Infused green tea (0.75% w/v, 180 mg total C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infused green tea (1.25% w/v)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infused green tea (1.75% w/v)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infused green tea (medium and high doses)
Number of subjects: 0
Study: 20841435

Group type: EXPERIMENTAL
Intervention: Norm group comparison
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norm group
Number of subjects: 0
Study: 17676393

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg q.d.) plus celecoxib (200 mg q.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg q.d.) plus naproxen (500 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (81 mg q.d.) plus placebo
Number of subjects: 0
Study: 16115324

Group type: EXPERIMENTAL
Intervention: New oscillometric device for measuring pulse wave velocity
Number of subjects: 44
Study: 12538214

Group type: EXPERIMENTAL
Intervention: Sameridine (25 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bupivacaine (15 mg)
Number of subjects: 24
Study: 10650110

Group type: EXPERIMENTAL
Intervention: High resolution CT (HRCT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cine MR
Number of subjects: 30
Study: 8712322

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg.kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 1505606

Group type: EXPERIMENTAL
Intervention: verapamil 40 mg every 8 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: verapamil 80 mg every 8 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: verapamil 120 mg every 8 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: theophylline alone (phase I)
Number of subjects: 12
Study: 6832463

Group type: EXPERIMENTAL
Intervention: Dothiepin three times a day (75 mg to 225 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dothiepin as a single night-time dose (75 mg to 225 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dothiepin three times a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dothiepin as a single night-time dose
Number of subjects: 30
Study: 31016471

Group type: EXPERIMENTAL
Intervention: Prenatal interpersonal sensitivity dimensions
Number of subjects: 812

Group type: COMPARATOR
Intervention: Control for depression symptoms
Number of subjects: 812
Study: 28958422

Group type: EXPERIMENTAL
Intervention: Vibration reducing gloves (VR gloves)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Leather glove
Number of subjects: 12
Study: 27842191

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab (Lucentis) in the sustained group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab (Lucentis) in the PRN group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall treatment with 0.3 mg ranibizumab (Lucentis)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab (Lucentis) overall
Number of subjects: 30
Study: 25077364

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ischemia-reperfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise plus ischemia-reperfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning plus ischemia-reperfusion
Number of subjects: 60
Study: 22989543

Group type: EXPERIMENTAL
Intervention: Peer auditing of mammographic screenings
Number of subjects: 311193

Group type: EXPERIMENTAL
Intervention: Traditional films
Number of subjects: 311193

Group type: EXPERIMENTAL
Intervention: Laser‐printed films
Number of subjects: 311193

Group type: COMPARATOR
Intervention: Control group (186 true negatives)
Number of subjects: 311193

Group type: EXPERIMENTAL
Intervention: False negative traditional films
Number of subjects: 311193
Study: 19026497

Group type: EXPERIMENTAL
Intervention: Nonlinear factor analysis
Number of subjects: 6259

Group type: EXPERIMENTAL
Intervention: Consumption items, age, and gender as predictors
Number of subjects: 6259

Group type: EXPERIMENTAL
Intervention: Latent class factor analysis
Number of subjects: 6259

Group type: EXPERIMENTAL
Intervention: Adjustment for consumption, age, and gender
Number of subjects: 6259
Study: 17250746

Group type: EXPERIMENTAL
Intervention: 1 l/min oxygen in air (50% oxygen)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2 l/min oxygen in air (50% oxygen)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 3 l/min (33% oxygen)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 3 l/min oxygen in nitrous oxide (33% oxygen)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lowest oxygen in air group (1 l/min)
Number of subjects: 32
Study: 15839740

Group type: EXPERIMENTAL
Intervention: co-artemether (six doses)
Number of subjects: 497

Group type: COMPARATOR
Intervention: CQ/SP (three doses of CQ and one dose of SP)
Number of subjects: 497
Study: 12020485

Group type: COMPARATOR
Intervention: Group A (2-3 leads with ST-segment elevation)
Number of subjects: 8731

Group type: EXPERIMENTAL
Intervention: Group B (4-5 leads with ST-segment elevation)
Number of subjects: 8731

Group type: EXPERIMENTAL
Intervention: Group C (6-7 leads with ST-segment elevation)
Number of subjects: 8731

Group type: EXPERIMENTAL
Intervention: Group D (more than 8 leads with ST-segment elevation)
Number of subjects: 8731
Study: 10453586

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture and routine treatments (group 1, n = 31)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine treatment (group 2, n = 33)
Number of subjects: 64
Study: 7530054

Group type: EXPERIMENTAL
Intervention: Fas antigen expression in acute myelogenous leukemia (AML)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fas antigen expression in acute lymphoblastic leukemia (ALL)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fas antigen expression in leukemic lymphoma
Number of subjects: 95

Group type: COMPARATOR
Intervention: Fas antigen expression in normal controls
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fas antigen expression in plasma cell leukemia
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Clinical relevance of Fas positivity in AML
Number of subjects: 95
Study: 1882025

Group type: EXPERIMENTAL
Intervention: Stress/type A behavior reduction program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (officer nonparticipants)
Number of subjects: 20
Study: 6808548

Group type: EXPERIMENTAL
Intervention: 8-min frequency counts collected over a period of 11 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Independently obtained rating scale scores
Number of subjects: 6
Study: 30919411

Group type: EXPERIMENTAL
Intervention: Cardiovascular screening examination using low-dose non-contrast CT, ankle and brachial BP measurements, and blood tests
Number of subjects: 16768

Group type: EXPERIMENTAL
Intervention: Cardiovascular screening examination
Number of subjects: 16768

Group type: EXPERIMENTAL
Intervention: Cardiovascular screening
Number of subjects: 16768
Study: 30376859

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 60
Study: 27170351

Group type: EXPERIMENTAL
Intervention: Qiaoshao Formula (QSF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dapoxetine
Number of subjects: 60
Study: 25154849

Group type: EXPERIMENTAL
Intervention: Continuous paravertebral nerve block (PVB) with 0.2% ropivacaine 250 ml in continuous infusion, assisted with intravenous morphine patient‐controlled analgesia.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CEA) with 0.2% ropivacaine 250 ml in continuous infusion, assisted with intravenous morphine patient‐controlled analgesia.
Number of subjects: 60
Study: 22134467

Group type: EXPERIMENTAL
Intervention: Moveable platform training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal walking trials (Control)
Number of subjects: 24
Study: 20662568

Group type: EXPERIMENTAL
Intervention: Wiki
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive Diagnostic Context
Number of subjects: 0
Study: 17215846

Group type: EXPERIMENTAL
Intervention: Tailored regimen based on CYP2C19 status and bacterial susceptibility to clarithromycin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard regimen (lansoprazole 30 mg b.i.d., clarithromycin 400 mg b.i.d., amoxicillin 750 mg b.i.d. for 1 week)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Tailored regimen
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 300
Study: 15130866

Group type: EXPERIMENTAL
Intervention: Active hip responses in older children
Number of subjects: 41

Group type: COMPARATOR
Intervention: Passive hip-dominant responses in least experienced walkers
Number of subjects: 41
Study: 12387471

Group type: EXPERIMENTAL
Intervention: Postnatal support group run weekly with a facilitator, starting two weeks postpartum.
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Postnatal support manual, posted two weeks postpartum.
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1004
Study: 9796225

Group type: EXPERIMENTAL
Intervention: Learning tasks (computer software package, building a model car) over a one‐, three‐, or five‐trial period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimates of playing time for melodies of varying familiarity (recently learned, well learned, extremely well learned) by novice and experienced pianists
Number of subjects: 0
Study: 7707448

Group type: EXPERIMENTAL
Intervention: 100 mg mebendazole
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2471
Study: 2616586

Group type: EXPERIMENTAL
Intervention: Isoxicam (200 mg/24 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Indomethacin (150 mg/24 h)
Number of subjects: 18
Study: 467194

Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus (MDA) during general anesthesia
Number of subjects: 156

Group type: COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy (LSS) during local anesthesia
Number of subjects: 156

Group type: COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy (LSS)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus (MDA)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus (MDA) and Lateral subcutaneous sphincterotomy (LSS)
Number of subjects: 156
Study: 31213097

Group type: EXPERIMENTAL
Intervention: Topical latanoprost therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 39
Study: 28560780

Group type: EXPERIMENTAL
Intervention: Natural agents (propolis, aloe vera, calendula, chamomile)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 25613308

Group type: EXPERIMENTAL
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 3035

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3035
Study: 22835005

Group type: EXPERIMENTAL
Intervention: Comprehensive nonsurgical periodontal therapy before 24 gestational weeks (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supragingival calculus removal (n = 30, control group)
Number of subjects: 60
Study: 22754923

Group type: EXPERIMENTAL
Intervention: O2 administered via nasal cannula for the first 10 minutes, followed by 10 minutes with O2 bar on without O2.
Number of subjects: 30

Group type: COMPARATOR
Intervention: O2 bar remained on without O2 being administered for the first 10 minutes, followed by 10 minutes of O2 via nasal cannula.
Number of subjects: 30
Study: 19309389

Group type: EXPERIMENTAL
Intervention: Step-up therapy (n = 293)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Step-down therapy (n = 226)
Number of subjects: 519
Study: 17365932

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + Losartan 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + Ramipril 5 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + Carvedilol 25 mg
Number of subjects: 21